NCT05900765View on ClinicalTrials.gov

A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

June 14, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2026

Conditions
Classical Hodgkin Lymphoma
Interventions
DRUG

Zimberelimab 240mg

"AVD regimen:~Doxorubicin 25mg/m2, d1, d15, IV; Vincristine 3mg/m2, d1, d15 IV; Dacarbazine 0.375mg/m2, d1, d15 IV"

Trial Locations (1)

510060

RECRUITING

Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou

All Listed Sponsors
collaborator

Guangzhou Gloria Biosciences Co., Ltd.

INDUSTRY

lead

Sun Yat-sen University

OTHER